Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

89.04 +1.26 (+1.44%)
Official Closing Price Updated: 7:00 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
2 Magnificent Growth Stocks to Buy Right Now
These two biotech stocks could be big winners for patient investors. 
Via The Motley Fool
1 Stock-Split Stock to Buy Hand Over Fist in October and 1 to Avoid
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's one historically cheap stock-split stock, as well as another company that carries... 
Via The Motley Fool
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.  
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
Via Benzinga
Is Novo Nordisk a Good Passive Income Stock?
Producing cash isn't a problem for this pharma giant. 
Via The Motley Fool
NYSE:NVO stands out as a growth opportunity that won't break the bank.
NYSE:NVO, a growth stock which is not overvalued. 
Via Chartmill
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
Benzinga 
Via Benzinga
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs,  
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Meet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505%
Soleno Therapeutics is working on a treatment for Prader Willi syndrome, a genetic disease that causes obesity. 
Via Investor's Business Daily
Why Shares of Structure Therapeutics Are Up Monday
The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug. 
Via The Motley Fool
Big Pharma's Weight Loss Drugs Vs. Snacking Industry: Who Will Prevail?
The rising prevalence of obesity and diabetes drugs like Novo Nordisk A/S's (NYSE: NVO) Wegovy and Ozempic is triggering concerns among investors about the future of the snacking industry.  
Via Benzinga
Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns
These biotech stocks, Thermo Fisher, Novo Nordisk, and Eli Lilly, will bring consistent returns in the volatile biotech sector. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023
Via Benzinga
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
Via AB Newswire
Topics Death
Exposures Death Product Safety
What A Government Shutdown Could Mean For You
In a nail-biting development amid fears of a government shutdown, the House has passed a bipartisan bill, narrowly averting the blackout as the midnight deadline looms. 
Via Benzinga
These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs
Stocks can offer a new buying opportunity with a pullback to the 50-day line. 
Via Investor's Business Daily
Why Shares of Structure Therapeutics Are Soaring on Friday
The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate. 
Via The Motley Fool
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66%
The company is working on a pill to help weight loss, rivaling shots from Novo and, possibly, Lilly. 
Via Investor's Business Daily
Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?
Structure Therapeutics Inc (NASDAQ: GPCR) released results from the Phase 1b multiple ascending dose (MAD) study of GSBR-1290 in healthy, overweight, or  
Via Benzinga
Novo Nordisk Targets High Demand Indian Market For Its Popular Obesity Drugs Like Wegovy
Danish pharma giant Novo Nordisk A/s (NYSE: NVO) has set its sights on India for the introduction of its breakthrough  
Via Benzinga
Why Abbott Says It Won't Be A Casualty Of The Weight-Loss Battle
Abbott and Dexcom stocks have tumbled as GLP-1 drugs have gripped the nation. 
Via Investor's Business Daily
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
The demand for biotech stocks is intense and is likely to only greatly increase going forward, especially in the United States. 
Via InvestorPlace
Despite Being Costly, Ozempic, Wegovy Prescriptions Surge 300% Over Three Years
An analytics firm Trilliant Health analysis revealed a significant surge in prescriptions for diabetes and obesity drugs like Ozempic and Wegovy during the 
Via Benzinga
Diabetes Prevalence Continues To Rise – Better Therapeutics' Digital Treatment Could Help Change This Trajectory
With the ever-increasing prevalence and staggering economic burden, the demand for innovative solutions to treat diabetes has never been higher 
Via Benzinga
Popular Weight Loss Drugs Ozempic and Wegovy Alert: FDA Adds Intestinal Blockage Warning
In a significant development, the FDA has updated the labeling for Novo Nordisk A/S's (NYSE: NVO) Ozempic, a diabetes drug known for its weight loss side effect, to include warnings about reports of... 
Via Benzinga
Exposures Product Safety
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE 
Via Benzinga
2 Magnificent Dividend Stocks to Buy Right Now
These two expensive dividend stocks are worth the price of admission. 
Via The Motley Fool
Which High-Profile Stock-Split Stock Is the Cheapest? Get Ready to Be Shocked...
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's one clear-cut stock-split stock that's notably cheaper than the rest. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.